Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01044303 · ClinicalTrials.gov registry record · Phase 4
Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)
A Phase 4 study of Transplant;Failure,Kidney, sponsored by East Carolina University.
- Completed
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT01044303: Completed Phase 4 study of Transplant;Failure,Kidney, sponsored by East Carolina University.
NCT01044303 is a Phase 4 study of Transplant;Failure,Kidney that has completed, run by East Carolina University. The registered enrollment target is 32 participants, below the 220-participant average among 8 other Transplant;Failure,Kidney trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01044303, a Phase 4 study of Transplant;Failure,Kidney, has completed, sponsored by East Carolina University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
Conditions Studied
Interventions
- DRUG Myfortic Escalation
Study Locations (1)
North Carolina
- East Carolina University - Greenville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2010-01 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT01044303 record still lists
NCT01044303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 220-participant average among 8 other Transplant;Failure,Kidney trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Transplant;Failure,Kidney appearing as the primary indexed condition, and to 1 intervention - of which Myfortic Escalation is the first listed.
NCT01044303 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01044303 about?
NCT01044303 is a clinical study titled "Reducing Donor Specific Antibody (DSA) Strength in Maintenance Kidney Transplant Recipients (DSA Study)". The purpose of this study is to demonstrate that increased dosages of mycophenolic acid in maintenance kidney transplant recipients may cause a reduction in donor-specific antibodies.
What is the current status of trial NCT01044303?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 2010-01. Estimated completion is 2013-04.
What conditions does trial NCT01044303 study?
This clinical trial studies the following conditions: Transplant;Failure,Kidney.
What interventions are being tested in trial NCT01044303?
The interventions under investigation include: Myfortic Escalation (DRUG).
Who is sponsoring clinical trial NCT01044303?
This trial is sponsored by East Carolina University, which has 58 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01044303 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Transplant;Failure,Kidney
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01044303's enrollment target sits among peer trials
32 7th of 8 higher than 2 of 8 other Transplant;Failure,Kidney trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Transplant;Failure,Kidney trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant
RECRUITING · Phase 4
-
Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus
COMPLETED · Phase 4
-
Abdominal Wall Transplant
RECRUITING · NA
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
-
Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant
RECRUITING · NA
-
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia